SHANGHAI, April 17, 2025 /PRNewswire/ -- Henlius (2696.HK) held its 2025 Global R&D Day themed "Collaborate to Create," gathering senior executives, experts, and industry leaders to discuss R&D advances, strategic planning, and cutting-edge therapies. The event attracted hundreds from academia, industry, and investment sectors.
Henlius showcased its robust innovative pipeline, including serplulimab (anti-PD-1 mAb), HLX22 (anti-HER2 mAb), and HLX43 (PD-L1 ADC), which aim to address unmet needs in lung and gastrointestinal cancers. HLX43, China's first and the world's second PD-L1 ADC, combines a proprietary antibody with MediLink's dual-release payload, demonstrating promising preclinical efficacy and good safety profiles. Meanwhile, HLX22 targets HER2-positive gastric cancer with a novel mechanism to block tumor signaling pathways, positioning it as a potential first-line therapy for the treatment of HER2 positive GC, as well as a potential treatment option in patients with HER2-positive cancers.
In addition to its innovative pipeline and portfolio, the company highlighted its three innovative technology platforms, including Hinova TCE (tri-specific T-cell engager) platform for solid tumors, the proprietary ADC platform Hanjugator, and the AI-driven drug discovery platform HAI Club, which have formed a collaborative R&D matrix to accelerate the development of differentiated therapies. Meanwhile, Henlius is strategically advancing the development of its proprietary hyaluronidase Henozye and subcutaneous injection technologies, accelerating formulations for novel drugs and biosimilars while extending product lifecycles.
Globalization remains a key focus for Henlius, with Japan prioritized as a strategic market under its "Internationalization 2.0" strategy. Henlius leverages Japan's aging population and regulatory environment to advance clinical trials for HLX22 and serplulimab (anti-PD-1), aiming to build an end-to-end value chain from R&D to commercialization. At the "Partnering for Success" panel, 2022 Nobel Laureate Prof. Carolyn Bertozzi highlighted the promise of sialoglycan-targeting therapies in oncology and immunology. Through the collaboration with Henlius, the development of human sialidase fusion protein HLX79 (E-602) has been accelerated. Industry leaders underscored Henlius' integrated capabilities in antibody development, clinical execution, and global-quality manufacturing as key drivers for forging high-impact alliances. Driven by "trust-driven" partnerships, the company expands its therapeutic ecosystem globally.
The event concluded with a call for industry-wide collaboration to bridge the preclinical-clinical gap, leveraging AI and data-driven strategies to accelerate patient-centric innovation. In 2025, Henlius aims to transform technological advancements into clinical value, reinforcing China's role in global biopharma.
View original content:https://www.prnewswire.co.uk/news-releases/henlius-2025-global-rd-day-harnessing-the-power-of-innovation-to-propel-global-strategy-to-new-heights-302431347.html
